Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ Phospho-EEF2K (Ser366) Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA5121303
This item is not returnable.
View return policy
Description
Positive test controls include: HeLa, NIH/3T3, C6. Immunogen sequence: TLSGS.
EEF2K is a highly conserved Serine/Threoning kinase in the calmodulin signaling pathway whose activity is increased in cancers including breast cancer. EEF2K (eukaryotic elongation factor 2 kinase) is a threonine kinase that regulates protein synthesis by controlling the rate of peptide chain elongation. Up activation, by a variety of upstream kinases including AMPK or TRPM7, EEF2K phosphorylates the elongation factor EEF2 at a single site. Then, EEF2K renders EEF2 unable to bind ribosomes and inactive - in turn, the rate of protein synthesis is reduced.
Specifications
Phospho-EEF2K (Ser366) | |
Polyclonal | |
Unconjugated | |
EEF2K | |
C86191; Calcium/calmodulin-dependent eukaryotic elongation factor 2 kinase; calcium/calmodulin-dependent eukaryotic elongation factor-2 kinase; calmodulin-dependent protein kinase III; EC 2.7.11.20; eEF-2 kinase; Eef2k; eEF-2K; EF2K; elongation factor 2 kinase; elongation factor-2 kinase; euk; eukaroytic elongation factor 2 kinase; eukaryotic elongation factor 2 kinase; eukaryotic elongation factor-2 kinase; HSU93850; kinase eEF2K; SMEF2K | |
Rabbit | |
Affinity Chromatography | |
RUO | |
13631, 25435, 29904 | |
-20°C, Avoid Freeze/Thaw Cycles | |
Liquid |
ELISA, Western Blot | |
2.86 mg/mL | |
PBS with 50% glycerol and 0.01% thimerosal; pH 7.3 | |
O00418, O08796, P70531 | |
EEF2K | |
A synthetic phosphorylated peptide around S366 of human EEF2K (NP_037434.1). | |
100 μL | |
Primary | |
Human, Mouse, Rat | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction